Moderna, Inc.
- Stock
- Ticker MRNA
- ISIN US60770K1079
- Nasdaq
Performance, volatility and drawdowns of Moderna, Inc. since 12/2018, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $5,649. Global equities (VT): $14,653.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −95.4% in 11/2025, measured from the peak in 08/2021. The old peak has not been reached again yet.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 966 | 108 | 142 | 1,016 | 678 | 389 | 145 | 1,313 |
| Gross profit | 227 | 18 | 23 | 809 | 226 | -566 | 52 | 995 |
| Operating income | -1,246 | -1,050 | -907 | -260 | -857 | -1,388 | -815 | 130 |
| EBITDA | -1,187 | -1,012 | -851 | -209 | -791 | -1,332 | -759 | 191 |
| Net income | -1,120 | -971 | -825 | -200 | -826 | -1,343 | -782 | 162 |
| Earnings per share | -2.91 | -2.52 | -2.13 | -0.51 | -2.11 | -3.40 | -1.97 | 0.38 |
| Balance sheet | ||||||||
| Total assets | 14,142 | 12,704 | 12,010 | 12,135 | 12,338 | 11,488 | 10,961 | 13,468 |
| Liabilities | 3,241 | 2,638 | 2,611 | 2,805 | 3,688 | 4,080 | 4,200 | 6,631 |
| Equity | 10,901 | 10,066 | 9,399 | 9,330 | 8,650 | 7,408 | 6,761 | 6,837 |
| Cash | 1,927 | 1,623 | 1,279 | 1,132 | 2,595 | 1,908 | 1,723 | 1,195 |
| Long-term debt | 0.0 | – | – | – | 590 | 590 | 591 | – |
| Cash flow | ||||||||
| Operating cash flow | 825 | -1,037 | -919 | -847 | 930 | -630 | -526 | -1,559 |
| Capital expenditure | -522 | -117 | -3.0 | -33 | -39 | -62 | -37 | -47 |
| Free cash flow | 303 | -1,154 | -922 | -880 | 891 | -692 | -563 | -1,606 |
Value it:DCF calculatorMultiples calculator
Annual returns
Best year 2020 at +434.1%, weakest 2024 at −58.2%. 3 of 7 full years were positive. * partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 6 Nov 2026 | $0.38 |
| 31 Jul 2026 | −$1.97 |
| 1 May 2026 | −$3.40 |
| 20 Feb 2026 | −$2.11 |
| 6 Nov 2025 | −$0.51 |
| 1 Aug 2025 | −$2.13 |
| 1 May 2025 | −$2.52 |
| 21 Feb 2025 | −$2.91 |
| 7 Nov 2024 | $0.03 |
| 1 Aug 2024 | −$3.33 |
| 2 May 2024 | −$3.07 |
| 23 Feb 2024 | $0.56 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €72bn
- Market cap in trading currency
- $78.9bn
- Enterprise value
- $73.7bn
- P/E
- –
- P/S
- 31.25
- P/B
- 11.54
- EV/Sales
- 29.20
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -2.5%
Results (last four quarters)
- Revenue
- $2.53bn
- Gross profit
- $707m
- EBITDA
- −$2.69bn
- Net income
- −$2.79bn
- Earnings per share
- −$7.10
- Revenue per share
- $6.24
- Revenue growth
- +29.2%
- Earnings growth
- –
Profitability
- Gross margin
- 28.0%
- Operating margin
- -116.0%
- Net margin
- -110.5%
- Return on equity
- -34.5%
- Return on assets
- -20.7%
Balance sheet and cash flow
- Cash
- $5.17bn
- Cash per share
- $12.78
- Financial debt
- –
- Debt/equity %
- –
- Current ratio
- 3.62
- Book value per share
- $16.90
- Operating cash flow
- −$1.79bn
- Free cash flow
- −$1.97bn
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 405m
- Volume
- 9.64m
- Avg. volume 3 months
- 22.2m
- Relative volume
- 0.6
Price and technicals
- Price
- $195.00
- 1 day
- −2.2%
- 52-week high
- $269.00
- 52-week low
- $22.36
- Distance to 52-week high
- −27.5%
- Distance to 52-week low
- +772.1%
- Distance to 50-day line
- −6.2%
- Distance to 200-day line
- +94.2%
- RSI (14)
- 41
- Volatility 1M
- 78.4%
Performance
- 1 week
- −12.7%
- 1 month
- −3.8%
- 3 months
- +40.4%
- 6 months
- +316.0%
- YTD
- +561.2%
- 1 year
- +706.5%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has MRNA performed since 12/2018?
$10,000 grew to $104,839 by 20 Nov 2026, which is +34.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is MRNA?
Volatility was 99.2% per year, measured on monthly returns. The largest decline from a peak was −95.4%, with the low in 11/2025.
How does MRNA compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.9% per year at 16.1% volatility, MRNA returned +34.4% at 99.2%. The correlation of monthly returns was 0.26; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.